Leidos Holdings, Inc. (LDOS)

Leidos Holdings reported third-quarter EPS of $3.62 on November 3, 2026, against an analyst estimate of $3.03, a beat of 19.47%, yet the stock fell 6.55% in the next session. The company has now beaten EPS estimates in each of its last eight reports, but the share price has moved lower after four of those beats. That split between earnings strength and price reaction is the central question for the stock at this point. Revenue grew 7.17% in the latest quarter year on year, well behind a sector median of 24.2%, and the market is weighing that slower top line against a valuation that sits far below peers. The stock closed at $133.89 after a 2.44% drop in the latest session. It sits about 3.9% above its 50-day average of $128.87 but below its 200-day average of $138.95, so the trend picture is mixed.

Leidos has beaten EPS estimates in all eight of the reports on record, including the $3.62 result on November 3, 2026 against $3.03 expected. The record is more mixed than the beat count suggests: four of the eight beats were followed by a lower share price on the next session, and four by a higher one. The largest move after any earlier report came on August 4, 2026, when the stock rose 10.01% after an EPS beat of 12.03%. Investors appear to be focused on the quality and direction of growth rather than the headline earnings figure alone.

Revenue grew 7.17% in the latest quarter compared with the same quarter a year earlier, which is 17.0 percentage points slower than the sector median of 24.2%. That gap is the main reason the revenue growth factor pulls the CleaRank score down most. Analysts expect revenue to grow 5.1% this fiscal year to about $18.0 billion, so the slower pace is expected to continue rather than being a single soft quarter. The company's net profit margin of 7.97% and operating margin of 12.05% show it is profitable, and return on equity of 28.27% is well above the sector median of 13.4%, but these figures do not offset slower top-line expansion.

At a trailing P/E of 11.97, Leidos trades 65.9% below the sector median P/E of 35.1, and its price-to-sales ratio of 0.92 is 87.9% below the sector median of 7.6. The dividend yield is 1.28% on an annual dividend of $1.72 per share. Analysts are more cautious than the earnings record suggests: JP Morgan downgraded the stock to Neutral from Overweight on October 8, 2026, while Citigroup kept its Buy rating on October 7, 2026. Insiders recorded 12 sales worth $10.1M over the last 18 months and no open-market purchases, although such sales are often planned in advance or made to cover tax on vesting shares.

The base case is that Leidos trades in a range set by its earnings beats on one side and slower revenue growth on the other. Analysts' estimates imply revenue growth of 5.1% this fiscal year and EPS growth of 5.5%, but EPS is expected to shrink 3.9% next year, which limits how much a beat can lift the shares. For the stock to move back toward the 200-day average near $138.95, the company would need to show that its revenue growth is closing the gap with the sector, not only that it beats estimates. The analysts' median 12-month target of $145.00 sits about 8.3% above the price, with a range from $120.00 to $225.00. A failure to hold the 50-day average near $128.87 would put the lowest analyst target of $120.00 in view as a reference point. Six of the 17 analysts rate the stock buy or strong buy, 11 rate it hold, and none rate it sell, so the consensus is Hold, and a further downgrade like the one from JP Morgan on October 8, 2026 would weigh on that view.

Support sits first at the 50-day simple moving average of $128.87, which is the nearest level below the price. Below that is the 52-week low of $98.86, a much deeper floor that the stock has not tested over the past year. Resistance sits first at the 20-day exponential moving average of $134.09, which is only slightly above the price and marks the nearest hurdle for a rebound. Next is the 200-day simple moving average of $138.95, the level that separates the mixed trend from a clearer recovery. The 52-week high of $205.00 is the most distant level above the price.